{"id":976144,"date":"2026-06-26T09:18:05","date_gmt":"2026-06-26T13:18:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/opus-genetics-added-to-the-russell-3000-russell-2000-and-russell-microcap-indexes\/"},"modified":"2026-06-26T09:18:05","modified_gmt":"2026-06-26T13:18:05","slug":"opus-genetics-added-to-the-russell-3000-russell-2000-and-russell-microcap-indexes","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/opus-genetics-added-to-the-russell-3000-russell-2000-and-russell-microcap-indexes\/","title":{"rendered":"Opus Genetics Added to the Russell 3000\u00ae, Russell 2000\u00ae and Russell Microcap\u00ae Indexes"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">RESEARCH TRIANGLE PARK, N.C., June  26, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=m5QKGzGeJtENkI2bVWgDn_mvAm_CEQs9_uTzkt_FodY2IJjZsWhSQKPzgCiFkIJQMoaejJEzWhXpLsnWNNL4UXotDOshW3L65QiJ9ctAeio=\" rel=\"nofollow\" target=\"_blank\">Opus Genetics, Inc.<\/a> (Nasdaq: IRD) (the \u201cCompany\u201d or \u201cOpus Genetics\u201d), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced the Company will be added as a member of the broad-market Russell 3000<sup>\u00ae<\/sup>, the Russell 2000<sup>\u00ae<\/sup> and the Russell Microcap<sup>\u00ae<\/sup> Indexes, effective when the U.S. market opens on June 29, 2026, as part of the June 2026 Russell indexes reconstitution.<\/p>\n<p>\u201cWe are pleased to be included in these Russell indexes, which provide validation of the progress we\u2019re making in advancing our gene therapies for inherited retinal diseases,\u201d said George Magrath, M.D., Chief Executive Officer of Opus Genetics. \u201cWe welcome the enhanced visibility within the investment community as we continue on our strategic path.\u201d<\/p>\n<p>The June reconstitution of the Russell US indexes captures up to the 4,000 largest US stocks as of April 30, ranking them by total market capitalization. Membership in the Russell 3000<sup>\u00ae<\/sup> Index, which remains in place until the next semi-annual reconstitution, means automatic inclusion in the large-cap Russell 1000<sup>\u00ae<\/sup> Index or small-cap Russell 2000<sup>\u00ae<\/sup> Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.<\/p>\n<p>Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to data as of the end of June 2025, approximately $12.2 trillion in assets were benchmarked against the Russell US indexes, which belong to FTSE Russell, the global index provider.<\/p>\n<p>\n        <strong>About Opus Genetics<\/strong>\n      <\/p>\n<p>Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company\u2019s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RDH12, MERTK, RHO, CNGB1 and NMNAT1. The Company is based in Research Triangle Park, NC. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iIUK31T5kZoDB-K3YJYrnUur0UyPuOYxhGfrlaHwZSBP3LOXetCR5feKQJ3ZnbDcP1gKY0lwgt7JMOM_BRFMaQ==\" rel=\"nofollow\" target=\"_blank\"><u>www.opusgtx.com<\/u><\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>This press release contains certain statements that are not statements of historical fact and are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements related to our inclusion in the Russell indexes and related benefits, the clinical development, clinical results, preclinical data and future plans for OPGx-LCA5, OPGx-BEST1, OPGx-MERTK, OPGx-RDH12, OPGx-RHO and earlier stage programs, and expectations regarding us, our business prospects and our results of operations, and are subject to certain risks and uncertainties posed by many factors and events that could cause our actual business, prospects and results of operations to differ materially from those anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those described under the heading \u201cRisk Factors\u201d included in our most recent Annual Report on Form 10-K for the year ended December 31, 2025, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, and in our other filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. These forward-looking statements are based upon our current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. In some cases, you can identify forward-looking statements by the following words: \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201caim,\u201d \u201cmay,\u201d \u201congoing,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould\u201d or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. We undertake no obligation to publicly update any forward-looking statements in order to reflect events or circumstances that might subsequently arise.<\/p>\n<p>\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p>\n        <strong>Investors<\/strong><br \/>\n        <br \/>Jenny Kobin<br \/>Remy Bernarda<br \/>IR Advisory Solutions<br \/>ir@opusgtx.com<\/p>\n<p>\n        <strong>Media<\/strong>\n      <\/p>\n<p>Kimberly Ha<br \/>KKH Advisors<br \/>917-291-5744<br \/>kimberly.ha@kkhadvisors.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MzIwNCM3NjgwMDkxIzIzMDE3NjA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NzMzMTk3ODQtYWYwZS00NTI5LTkzYjctNTY2OTc0YTEwM2Q3LTEzMTMzMTAtMjAyNi0wNi0yNi1lbg==\/tiny\/Opus-Genetics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>RESEARCH TRIANGLE PARK, N.C., June 26, 2026 (GLOBE NEWSWIRE) &#8212; Opus Genetics, Inc. (Nasdaq: IRD) (the \u201cCompany\u201d or \u201cOpus Genetics\u201d), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced the Company will be added as a member of the broad-market Russell 3000\u00ae, the Russell 2000\u00ae and the Russell Microcap\u00ae Indexes, effective when the U.S. market opens on June 29, 2026, as part of the June 2026 Russell indexes reconstitution. \u201cWe are pleased to be included in these Russell indexes, which provide validation of the progress we\u2019re making in advancing our gene therapies for inherited retinal diseases,\u201d said George Magrath, M.D., Chief Executive Officer of Opus Genetics. \u201cWe &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/opus-genetics-added-to-the-russell-3000-russell-2000-and-russell-microcap-indexes\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Opus Genetics Added to the Russell 3000\u00ae, Russell 2000\u00ae and Russell Microcap\u00ae Indexes&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-976144","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Opus Genetics Added to the Russell 3000\u00ae, Russell 2000\u00ae and Russell Microcap\u00ae Indexes - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/opus-genetics-added-to-the-russell-3000-russell-2000-and-russell-microcap-indexes\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Opus Genetics Added to the Russell 3000\u00ae, Russell 2000\u00ae and Russell Microcap\u00ae Indexes - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"RESEARCH TRIANGLE PARK, N.C., June 26, 2026 (GLOBE NEWSWIRE) &#8212; Opus Genetics, Inc. (Nasdaq: IRD) (the \u201cCompany\u201d or \u201cOpus Genetics\u201d), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced the Company will be added as a member of the broad-market Russell 3000\u00ae, the Russell 2000\u00ae and the Russell Microcap\u00ae Indexes, effective when the U.S. market opens on June 29, 2026, as part of the June 2026 Russell indexes reconstitution. \u201cWe are pleased to be included in these Russell indexes, which provide validation of the progress we\u2019re making in advancing our gene therapies for inherited retinal diseases,\u201d said George Magrath, M.D., Chief Executive Officer of Opus Genetics. \u201cWe &hellip; Continue reading &quot;Opus Genetics Added to the Russell 3000\u00ae, Russell 2000\u00ae and Russell Microcap\u00ae Indexes&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/opus-genetics-added-to-the-russell-3000-russell-2000-and-russell-microcap-indexes\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-26T13:18:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MzIwNCM3NjgwMDkxIzIzMDE3NjA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opus-genetics-added-to-the-russell-3000-russell-2000-and-russell-microcap-indexes\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opus-genetics-added-to-the-russell-3000-russell-2000-and-russell-microcap-indexes\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Opus Genetics Added to the Russell 3000\u00ae, Russell 2000\u00ae and Russell Microcap\u00ae Indexes\",\"datePublished\":\"2026-06-26T13:18:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opus-genetics-added-to-the-russell-3000-russell-2000-and-russell-microcap-indexes\\\/\"},\"wordCount\":716,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opus-genetics-added-to-the-russell-3000-russell-2000-and-russell-microcap-indexes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1MzIwNCM3NjgwMDkxIzIzMDE3NjA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opus-genetics-added-to-the-russell-3000-russell-2000-and-russell-microcap-indexes\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opus-genetics-added-to-the-russell-3000-russell-2000-and-russell-microcap-indexes\\\/\",\"name\":\"Opus Genetics Added to the Russell 3000\u00ae, Russell 2000\u00ae and Russell Microcap\u00ae Indexes - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opus-genetics-added-to-the-russell-3000-russell-2000-and-russell-microcap-indexes\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opus-genetics-added-to-the-russell-3000-russell-2000-and-russell-microcap-indexes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1MzIwNCM3NjgwMDkxIzIzMDE3NjA=\",\"datePublished\":\"2026-06-26T13:18:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opus-genetics-added-to-the-russell-3000-russell-2000-and-russell-microcap-indexes\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opus-genetics-added-to-the-russell-3000-russell-2000-and-russell-microcap-indexes\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opus-genetics-added-to-the-russell-3000-russell-2000-and-russell-microcap-indexes\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1MzIwNCM3NjgwMDkxIzIzMDE3NjA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1MzIwNCM3NjgwMDkxIzIzMDE3NjA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opus-genetics-added-to-the-russell-3000-russell-2000-and-russell-microcap-indexes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Opus Genetics Added to the Russell 3000\u00ae, Russell 2000\u00ae and Russell Microcap\u00ae Indexes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Opus Genetics Added to the Russell 3000\u00ae, Russell 2000\u00ae and Russell Microcap\u00ae Indexes - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/opus-genetics-added-to-the-russell-3000-russell-2000-and-russell-microcap-indexes\/","og_locale":"en_US","og_type":"article","og_title":"Opus Genetics Added to the Russell 3000\u00ae, Russell 2000\u00ae and Russell Microcap\u00ae Indexes - Market Newsdesk","og_description":"RESEARCH TRIANGLE PARK, N.C., June 26, 2026 (GLOBE NEWSWIRE) &#8212; Opus Genetics, Inc. (Nasdaq: IRD) (the \u201cCompany\u201d or \u201cOpus Genetics\u201d), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced the Company will be added as a member of the broad-market Russell 3000\u00ae, the Russell 2000\u00ae and the Russell Microcap\u00ae Indexes, effective when the U.S. market opens on June 29, 2026, as part of the June 2026 Russell indexes reconstitution. \u201cWe are pleased to be included in these Russell indexes, which provide validation of the progress we\u2019re making in advancing our gene therapies for inherited retinal diseases,\u201d said George Magrath, M.D., Chief Executive Officer of Opus Genetics. \u201cWe &hellip; Continue reading \"Opus Genetics Added to the Russell 3000\u00ae, Russell 2000\u00ae and Russell Microcap\u00ae Indexes\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/opus-genetics-added-to-the-russell-3000-russell-2000-and-russell-microcap-indexes\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-26T13:18:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MzIwNCM3NjgwMDkxIzIzMDE3NjA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opus-genetics-added-to-the-russell-3000-russell-2000-and-russell-microcap-indexes\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opus-genetics-added-to-the-russell-3000-russell-2000-and-russell-microcap-indexes\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Opus Genetics Added to the Russell 3000\u00ae, Russell 2000\u00ae and Russell Microcap\u00ae Indexes","datePublished":"2026-06-26T13:18:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opus-genetics-added-to-the-russell-3000-russell-2000-and-russell-microcap-indexes\/"},"wordCount":716,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opus-genetics-added-to-the-russell-3000-russell-2000-and-russell-microcap-indexes\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MzIwNCM3NjgwMDkxIzIzMDE3NjA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opus-genetics-added-to-the-russell-3000-russell-2000-and-russell-microcap-indexes\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/opus-genetics-added-to-the-russell-3000-russell-2000-and-russell-microcap-indexes\/","name":"Opus Genetics Added to the Russell 3000\u00ae, Russell 2000\u00ae and Russell Microcap\u00ae Indexes - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opus-genetics-added-to-the-russell-3000-russell-2000-and-russell-microcap-indexes\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opus-genetics-added-to-the-russell-3000-russell-2000-and-russell-microcap-indexes\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MzIwNCM3NjgwMDkxIzIzMDE3NjA=","datePublished":"2026-06-26T13:18:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opus-genetics-added-to-the-russell-3000-russell-2000-and-russell-microcap-indexes\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/opus-genetics-added-to-the-russell-3000-russell-2000-and-russell-microcap-indexes\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opus-genetics-added-to-the-russell-3000-russell-2000-and-russell-microcap-indexes\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MzIwNCM3NjgwMDkxIzIzMDE3NjA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MzIwNCM3NjgwMDkxIzIzMDE3NjA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opus-genetics-added-to-the-russell-3000-russell-2000-and-russell-microcap-indexes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Opus Genetics Added to the Russell 3000\u00ae, Russell 2000\u00ae and Russell Microcap\u00ae Indexes"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/976144","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=976144"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/976144\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=976144"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=976144"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=976144"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}